Beta-elemene treatment is associated with improved outcomes of patients with esophageal squamous cell carcinoma. (December 2017)

• Record Type: Journal Article
• Authors: Chang, Zhiwei; Gao, Ming; Zhang, Weijie; Song, Lijie; Jia, Yongxu; Qin, Yanru
• Is Part Of: Surgical oncology. Volume 26:Number 4(2017)
• Page Start: 333
• Page End: 337
• Publication Date: 2017-12
• Subjects: β-Elemene -- Esophageal squamous cell carcinoma -- Prognosis -- Overall survival -- Progression-free survival; Cancer -- Surgery -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Electronic journals; 616.994059
• DOI: 10.1016/j.suronc.2017.07.002
• Languages: English
• ISSNs: 0960-7404

Abstract

Abstract: Purpose: To investigate the therapeutic effects of concurrent preoperative β-elemene treatment in patients with esophageal squamous cell carcinoma who received concurrent chemoradiotherpay followed by surgery. Method: The clinicopathological parameters and outcomes of 102 patients with esophageal squamous cell carcinoma were studied and compared between patients treated with and without β-elemene. Results: β-elemene treatment could prolong the overall survival and progression-free survival. The 3-year overall survival rate was also increased by β-elemene treatment. β-elemene treatment was an independent prognostic factor for both overall survival and progression-free survival. Occurrence of toxicities associated with chemoradiotherapy was decreased by β-elemene treatment. Conclusions: Findings in this study suggested that β-elemene treatment provided survival benefits and reduced chemoradiotherapy-associated toxicities in patients with esophageal squamous cell carcinoma. Highlights: β-elemene were first studied in patients with esophageal cancer. β-elemene provided survival benefits in patients with esophageal cancer. β-elemene reduced toxicities associated with chemoradiotherapy. β-elemene was an independent prognostic factor in patients with esophageal cancer.